The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

Gene Holdings Inc. remains a Buy, driven by promising LEGEND trial data for detalimogene voraplasmid. Learn more about ENGN stock here.

Cancer mortality rates continue to fall in Canada, driven by decreases in the death rates from lung and colorectal cancer, ...

The robust 77.8% three-month CR rate observed in the UTOPIA trial is highly encouraging and reinforces the potential of UGN-103 to deliver meaningful benefits to patients,” said Liz Barrett, President ...

-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...

San Diego YouTuber Mikey Rijavec is reportedly missing after he issued a mayday call while he was 8 miles away from the ...

The Los Angeles Dodgers defeated the Toronto Blue Jays, 6-5, in an epic 18-inning World Series game, and the man who called ...

Due to the litigation Pfizer filed Friday and Monday against Metsera, Novo Nordisk and the biotech’s lead shareholder, CEO ...

And despite the sales slump in the U.S. this past quarter, Pfizer’s Prevnar dynasty still leads in pediatric pneumococcal vaccination worldwide and among conjugated pneumococcal vaccines for adults in ...

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

Johnson & Johnson JNJ and MerckMRK are leading U.S. healthcare giants, making them natural peers for a head-to-head comparison. Both companies have a strong presence in oncology, ...

Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, expectations were $-2.15. Operator: Good day, and thank you for standing by.